Anti-Müllerian Hormone as a Sensitive Marker of Ovarian Function in Young Cancer Survivors

Table 1

Characteristic of patients classified according to different risk groups and related treatment.

Diagnosis	𝑛	Age at diagnosis (y)	Age at exam (y)	Time off treatment (y)	Chemotherapy (doses of gonadotoxic chemotherapeutics)	Radiotherapy
HR	38
HL	22	15.2±2.6	21.35±4.4	6.03±3.8
IIA, IIB	12				3 × MVPP + 3 × B-DOPA; Dacarbazine 900 mg/m^2; Procarbazine 3000 mg/m^2; Nitrogen mustard 36 mg/m^2	Supradiaphragm 20 Gy
IIIA	7				3 × MVPP + 3 × B-DOPA	Supradiaphragm 20 Gy; Infradiaphragm 15 Gy
IIIB	3				4 × MVPP + 4 × B-DOPA; Dacarbazine 1200 mg/m^2; Procarbazine 4000 mg/m^2; Nitrogen mustard 48 mg/m^2	Supradiaphragm 20 Gy; Infradiaphragm 15 Gy
BMT	6				Busulphane 3 × 16 mg/kg/day; Cyclophosphamide; 4 × 0.2 g/kg/day
CML; AML; ALL	2; 2; 2					TBI 12 Gy (1 pt)
STS II/III	3				CWS 90; Ifosfamide 37.5 g/m^2; (Actinomycin D, vincristine); Dacarbazine 2.25 g/m^2; Cyclophosphamide 5 g/m^2	Supradiaphagm 20 Gy (1 pt); Infradiaphragm (49.6 Gy—1 pt, 25 Gy—1 pt)
NHL III	1				LMB; Cyclophosphamide 5.8 g/m^2	Infradiaphragm 15 Gy
Wilms tumor	6				SIOP; (Actinomycin D, vincristine, and epirubicine)	Infradiaphagm; 15 Gy—2 pts; 20 Gy—2 pts; 25 Gy—1 pt; 40 Gy—1 pt
III-5; V-1					Ifosfamide 36, actinomycin D, and vincristine
MR	12	8.04±5.5	18.36±5.7	8.7±4.4
AML	2				AML—BFM 90; Cytarabine 44.7 g/m^2	CNS—18 Gy
STS II	3				CWS 96; Ifosfamide 37.5 g/m^2—1 pt; 42 g/m^2—1 pt; 48 g/m^2—1 pt	Supradiaphragm 20 Gy
NBL II	2				PACE; Cisplatin—2 g/m^2	—
NHL II	5				BFM 95; Cyclophosphamide 3 g/m^2; Ifosfamide 8 g/m^2	—
LR	33	7.8±5.3	17.25±5.0	9.0±4.8
ALL	22				BFM 90; Cyclophosphamide—3.0 g/m^2	CNS 12 Gy—5 pts; CNS 18 Gy—2 pts
Germinal tumors	7				Without cht—4; TGM 95; (Cisplatin, ifosfamide, and etoposide)	Unilateral ovariectomy (7)
Wilms tumor II	5				Actinomycin D, vincristine

HR: high risk group, MR: medium risk group, LR: low risk group, HL: Hodgkin lymphoma, BMT: bone marrow transplantation, CML: chronic myeloid leukemia, AML: acute myeloid leukemia, ALL: acute lymphoblastic leukemia, STS: soft tissue sarcoma, NHL: non-Hodgkin lymphoma, NBL: neuroblastoma, CNS: central nervous system, and TBI: total body irradiation.